The effect of low-dose human growth hormone [somatropin] therapy in HIV infected patients on highly active antiretroviral therapy (HAART)

Next Previous
Trial Profile

The effect of low-dose human growth hormone [somatropin] therapy in HIV infected patients on highly active antiretroviral therapy (HAART)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Somatrogon (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jul 2008 Status changed from active, no longer recruiting to completed.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top